News

Biopharma news, November 10, 2026

The most important drug and company news of November 10, 2026, ranked, each linked to its Gosset profiles.

  1. Approval

    FDA approves Bayer's asundexian, the first factor XIa inhibitor, to prevent repeat stroke

    Sunharbo 50 mg, taken with antiplatelet therapy, is now approved for adults who recently had a non-cardioembolic ischemic stroke or a high-risk TIA. In the Phase 3 OCEANIC-STROKE trial, adding it cut ischemic stroke by 26% compared with antiplatelets alone, and major bleeding rates were reported as similar. China also approved the drug recently.

    Source types: Press release · News article. Sources are available to Gosset users. Log in to see them.

  2. Pivotal readout

    Alnylam's five-year HELIOS-B data favor starting vutrisiran early in ATTR-CM

    Patients treated with Amvuttra throughout the extension had a 41% lower five-year risk of death or recurrent cardiovascular events than those who started roughly three years later. Those p-values were nominal, with no correction for multiple testing. A separate exploratory look at 48 patients found exercise capacity was preserved over two years compared with placebo.

    Source types: Press release. Sources are available to Gosset users. Log in to see them.

  3. Pivotal readout

    Novartis reports two-year ianalumab data showing deeper control of Sjögren's disease

    In the NEPTUNUS extension, patients on monthly ianalumab had an average ESSDAI drop of 7.5 points by week 108, and 65.1% reached low disease activity. Those who moved from placebo to the drug at week 60 also improved, and adverse event rates were similar across arms. Several regulators are reviewing ianalumab, and Novartis expects an FDA decision in 2026.

    Source types: Press release. Sources are available to Gosset users. Log in to see them.

  4. Licensing & partnership

    AbbVie licenses Nxera's oral EP4 agonist for IBD for up to $1.47 billion

    AbbVie gains worldwide rights to NXE0033744, a gut-selective oral EP4 receptor agonist for inflammatory bowel disease. Nxera gets $100 million upfront, as much as $1.37 billion more in milestones, and tiered royalties, subject to antitrust clearance. A finished Phase 1 study supported the candidate's gut selectivity and target engagement.

    Source types: News article. Sources are available to Gosset users. Log in to see them.

  5. Pivotal readout

    J&J's CAPLYTA succeeds in second Phase 3 trial in bipolar I mania

    In Study 452, lumateperone cut YMRS scores by 3.7 points more than placebo at three weeks, and 43.9% of patients responded, compared with 23.7% on placebo. Dizziness, dry mouth and sedation were among the common side effects. With two positive Phase 3 trials, Johnson & Johnson plans to file with the FDA for this use.

    Source types: Press release. Sources are available to Gosset users. Log in to see them.

  6. Approval

    Bahrain approves Gan & Lee's insulin glargine prefilled pen

    Bahrain's health regulator registered Gan & Lee Pharmaceuticals' insulin glargine in a prefilled pen. Bahrain follows the UAE and Oman as the third Gulf Cooperation Council market to clear the product. Roughly 197,600 adults there were living with diabetes in 2024, a prevalence of 17.8%.

    Source types: News article. Sources are available to Gosset users. Log in to see them.

  7. Designation

    China's CDE proposes breakthrough status for Lepu's CDH17 ADC MRG007 in colorectal cancer

    The proposed designation covers advanced colorectal cancer that has progressed on two or more prior lines of systemic therapy. MRG007 is in a Phase Ib/II combination trial in China and won FDA orphan status in pancreatic cancer last month. ArriVent BioPharma holds rights outside Greater China under a January 2025 license valued at up to $1.207 billion.

    Source types: News article. Sources are available to Gosset users. Log in to see them.

  8. Financing

    Delix raises $100 million Series C to move zalsupindole into Phase IIb depression study

    JJDC and the Dementia Discovery Fund led the round. The money funds a Phase IIb proof-of-concept trial of the neuroplastogen in recurrent major depressive disorder, due to begin in early 2027. In a Phase Ib study, depression scores fell about 50% on average after a week.

    Source types: Press release. Sources are available to Gosset users. Log in to see them.

  9. Financing

    Kesmalea becomes Oyster Therapeutics and raises $60 million for tau degraders

    The London protein-degrader company, now called Oyster Therapeutics, has raised $60 million in a Series A-2 round led by 4BIO Capital. The money will push its lead tau degrader, an oral drug designed to reach the brain, toward the clinic and support the SELFTAC platform. Oyster is also funding tau biology research at Massachusetts General Hospital.

    Source types: Press release. Sources are available to Gosset users. Log in to see them.

  10. Financing

    PsiThera raises $25 million for oral immunology drugs, with AbbVie Ventures joining

    PsiThera closed a $25 million round that brings in AbbVie Ventures and Lumination Capital alongside its earlier backers. The money is meant to pick an oral TNF-alpha inhibitor candidate, start the studies needed before human testing, and move its oral TL1A inhibitors into lead optimization.

    Source types: Press release. Sources are available to Gosset users. Log in to see them.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call